Malaria Vaccines: What we need for success - PowerPoint PPT Presentation

1 / 18
About This Presentation
Title:

Malaria Vaccines: What we need for success

Description:

... the Parasite Lifecycle. Prevent the spread of parasites by ... No vaccine against a parasite. No known correlates of immunity. No 'market' What will it take? ... – PowerPoint PPT presentation

Number of Views:1286
Avg rating:3.0/5.0
Slides: 19
Provided by: pmck8
Category:

less

Transcript and Presenter's Notes

Title: Malaria Vaccines: What we need for success


1
Malaria VaccinesWhat we need for success
Christian Loucq, MD Director, PATH Malaria
Vaccine Initiative 8 July 2008 UK All-Party
Parliamentary Malaria Group
2
Why Im Here To Answer Three Questions
  • What is the PATH Malaria Vaccine Initiative
    (MVI)?
  • Why a vaccine?
  • What will it take?

3
To accelerate the development of malaria vaccines
and ensuretheir availability and accessibility
in the developing world
A world free from malaria
Founded in 1999 Donors Bill Melinda Gates
FoundationUS Agency for International
Development, ExxonMobil, private individuals
4
To accelerate the development of malaria vaccines
and ensuretheir availability and accessibility
in the developing world
  • Availability
  • Global access
  • Regulatory policy pathways
  • Accessibility
  • Preparing countries for the vaccine introduction
  • Decision-making framework

A world free from malaria
5
MVI A global programof PATH
6
Why a Malaria Vaccine?
7
Why a Malaria Vaccine?Age Distribution of Severe
Malaria
Gupta et al., Nature Medicine 5 340-342, 1999
0.14 0.12 0.1 0.08 0.06 0.04 0.02 0
Proportion Affected
1-2 mos
3-4 mos
5-6 mos
6-12 mos
1 2 3 4 5
6 7 8 9
Age group
8
Targeting the Parasite Lifecycle
9
Research and Development Strategy
10
Phase 1a Phase 1/2a
Phase 1b
Phase 2b
Construct Selection
Process Development
Final Formulation
Toxicology
GSK RTS,S AS01/AS02
Sanaria PfSPZ
Product Candidates
Targets P. vivax
Pre-erythroctyic (liver)
Pre-erythroctyic (liver)
ICGEB/BBIL PvRII
LaTrobe MSP2 ISA720
GenVec Ad5-CSP LSA1Ag2 Ad5-MSP1 AMA1
Monash MSP4
Blood-stage
MVDB AMA1-C1 ISA720
Research Programs
WRAIR/GSK AMA1 AS01/AS02
Adjuvanted Recombinant Proteins Viral
Vectored Live Attenuated (weakened)
11
RTS,S Clinical Research Center Network
IRSS - Centre Muraz
KHRC, Kintampo KCCR, Kumasi
KEMRI - Kisumu
HAS, Lambarene
KEMRI - Kilifi
JMP, Korogwe
IHDRC, Bagamoyo
KCH, Lilongwe
CISM, Manhiça
RTS,S MVI-GSK Program in Africa
12
WHO Vaccine PrioritizationVaccines that may be
licensed by 2012(WHO SAGE, November 2007)
Weighted priority score based upon expert opinion
13
Sanaria A Different Approach
  • Targets the whole parasite
  • Uses a live, attenuated parasite

14
Challenges What will it take?
  • No vaccine against a parasite
  • No known correlates of immunity
  • No market

15
What will it take? Strong partners
16
What will it take? Sustained commitment
17
Partners Today and Tomorrow
18
  • What can you do?
  • Support investments in malaria control today
  • Advocate now for investments in the tools for
    tomorrow
  • And
Write a Comment
User Comments (0)
About PowerShow.com